Prescription Drugs Market Research Reports & Industry Analysis
The prescription drugs industry is a key cornerstone of healthcare, delivering vital medications that improve and save lives. As this industry continues to evolve, understanding its nuances can be an ongoing challenge. MarketResearch.com provides hundreds of authoritative prescription drugs market research reports to help stakeholders understand the shifting market landscape and devise effective business strategies.
The Latest Prescription Drugs Market Analysis
- We provide data-packed reports on a wide range of product types, therapeutic areas, regions, and companies.
- Our research includes in-depth analyses of prescription drug market size, growth forecasts, and drivers and challenges.
- In addition, we cover the rise of personalized medicine and gene therapies, as well as regulatory issues and pricing models.
Your Dedicated Research Partner
As the prescription drugs industry shifts and changes, MarketResearch.com equips you with the tools to thrive. Trusted for decades as a reliable research partner, our clients include top pharmaceutical companies, investment banks, and universities. Whether you are exploring new markets or seeking to futureproof your business, our prescription drugs industry research reports offer a wealth of knowledge to inform your strategy. Get started by exploring our vast selection of reports on the prescription drugs industry today.
Prescription Drugs Industry Research & Market Reports
-
SMYRAF Drug Insight and Market Forecast – 2032
... Arthritis in Japan for the study period 2019–2032 is provided in this report along with a detailed description of the SMYRAF for Rheumatoid Arthritis. The report provides insight about mechanism of action, dosage and administration, ... Read More
-
JYSELECA Drug Insight and Market Forecast – 2032
... Rheumatoid Arthritis in the 6MM, i.e., EU4 (Germany, France, Italy, Spain), and the United Kingdom, and Japan for the study period 2019–2032 is provided in this report along with a detailed description of the JYSELECA ... Read More
-
Lenvatinib + pembrolizumab Emerging Drug Insight and Market Forecast – 2032
... in the 7MM. A detailed picture of the Lenvatinib + pembrolizumab for Metastatic Colorectal Cancer in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study ... Read More
-
RINVOQ Market Drug Insight and Market Forecast − 2032
... picture of the RINVOQ for atopic dermatitis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 –2032 is provided in this report ... Read More
-
Treprostinil sodium Drug Insight and Market Forecast – 2032
... of the Treprostinil sodium for Pulmonary Arterial Hypertension in the 6MM, i.e., United States, and EU5 (Germany, France, Italy, Spain, and the United Kingdom), for the study period 2019–2032 is provided in this report along ... Read More
-
Favezelimab (MK-4280) Emerging Drug Insight and Market Forecast – 2035
... detailed picture of the Favezelimab (MK-4280) for LAG-3 Next-generation Immunotherapies in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2035 is provided in ... Read More
-
JYSELECA Market Drug Insight and Market Forecast − 2032
... picture of the JYSELECA for ulcerative colitis in the 7MM, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in ... Read More
-
LYNPARZA Drug Insight and Market Forecast – 2032
... of the LYNPARZA for ER+ve HER2-ve Breast Cancer in the United States for the study period 2019–2032 is provided in this report along with a detailed description of the LYNPARZA for ER+ve HER2-ve Breast Cancer. ... Read More
-
Giredestrant Emerging Drug Insight and Market Forecast – 2032
... detailed picture of the Giredestrant for ER+ve HER2-ve Breast Cancer in the United States for the study period 2019–2032 is provided in this report along with a detailed description of the Giredestrant for ER+ve HER2-ve ... Read More
-
COMP 360 Emerging Drug Insight and Market Forecast – 2032
... markets. A detailed picture of the COMP 360 for Bipolar Depression in the 7MM, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, and Japan for the study period 2019 ... Read More
-
Capivasertib Emerging Drug Insight and Market Forecast – 2032
... detailed picture of the Capivasertib for ER+ve HER2-ve Breast Cancer in the United States for the study period 2019–2032 is provided in this report along with a detailed description of the Capivasertib for ER+ve HER2-ve ... Read More
-
Zamicastat Emerging Drug Insight and Market Forecast – 2032
... the Zamicastat for Pulmonary Arterial Hypertension in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report along with ... Read More
-
RG6139 (RO7247669) Emerging Drug Insight and Market Forecast – 2035
... detailed picture of the RG6139 (RO7247669) for LAG-3 Next-generation Immunotherapies in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2035 is provided in ... Read More
-
ENBREL Drug Insight and Market Forecast – 2032
... Rheumatoid Arthritis in the 7MM, i.e., United States, EU4 (Germany, France, Italy, Spain), and the United Kingdom, and Japan for the study period 2019–2032 is provided in this report along with a detailed description of ... Read More
-
MM-120 Emerging Drug Insight and Market Forecast – 2032
... detailed picture of the MM-120 for Generalized Anxiety Disorder in the 7MM, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, and Japan for the study period 2019–2032 is provided ... Read More
-
Cobitolimod Emerging Drug Insight and Market Forecast − 2032
... picture of the cobitolimod for ulcerative colitis in the 7MM, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in ... Read More
-
Attention Deficit Hyperactivity Disorder Market Share, Size, Trends, Industry Analysis Report, By Drug Type (Stimulants, and Non-Stimulants); By Demographics; By Distribution Channel; By Region; Segment Forecast, 2023-2032
... is expected to reach USD 32.14 billion by 2032, according to a new study by Polaris Market Research. The report “Attention Deficit Hyperactivity Disorder Market Share, Size, Trends, Industry Analysis Report, By Drug Type (Stimulants, ... Read More
-
Melflufen Emerging Drug Insight and Market Forecast – 2032
... Melflufen for AL Amyloidosis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report along with a detailed ... Read More
-
FS118 Emerging Drug Insight and Market Forecast – 2035
... the FS118 for LAG-3 Next-generation Immunotherapies in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2035 is provided in this report along with ... Read More
-
Ingrezza Emerging Drug Insight and Market Forecast – 2032
... Ingrezza for Huntington’s disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan, for the study period 2019–2032 is provided in this report along with a ... Read More
-
HUMIRA Market Drug Insight and Market Forecast − 2032
... picture of the HUMIRA for ulcerative colitis in the 7MM, i.e., United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan, for the study period 2019 –2032 is provided in this report along ... Read More
-
REMICADE Market Drug Insight and Market Forecast − 2032
... picture of the REMICADE for ulcerative colitis in the 7MM, i.e., United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan, for the study period 2019 –2032 is provided in this report along ... Read More
-
PIQRAY Drug Insight and Market Forecast – 2032
... of the PIQRAY for ER+ve HER2-ve Breast Cancer in the United States for the study period 2019–2032 is provided in this report along with a detailed description of the PIQRAY for ER+ve HER2-ve Breast Cancer. ... Read More
-
VERZENIO Drug Insight and Market Forecast – 2032
... of the VERZENIO for ER+ve HER2-ve Breast Cancer in the United States for the study period 2019–2032 is provided in this report along with a detailed description of the VERZENIO for ER+ve HER2-ve Breast Cancer. ... Read More
-
Mirikizumab Emerging Drug Insight and Market Forecast − 2032
... picture of the mirikizumab for ulcerative colitis in the 7MM, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in ... Read More
Research Assistance
